ASGCT 28th Annual Meeting, New Orleans, May 13-17, 2025

The ASGCT Annual Meeting is the premier event for the gene and cell therapy community—uniting scientists, clinicians, industry leaders, and patient advocates to drive progress in this transformative field. With a focus on cutting-edge research and clinical advancements, ASGCT fosters collaboration across disciplines to accelerate the development and delivery of life-changing therapies. PackGene is excited to join this year’s meeting, where we’re highlighting how our high-performance AAV, lentiviral, mRNA, and plasmid platforms are empowering innovation from bench to bedside. Whether enabling foundational research, supporting preclinical studies, or advancing therapeutic manufacturing, our end-to-end solutions are helping turn the promise of gene and cell therapies into reality.

Date: May 13-17, 2025
Venue: New Orleans Ernest N. Morial Convention Center, New Orleans, LA
Booth: 1821
Contact: Irene Song, Sr. Director Global Product, irene.song@packgene.com

Date: Friday, May 16

Time: 2:00-2:15pm

Location: Exhibit Hall Presentation Theater (Halls G-H, First Floor)

Abstract: Adeno-associated virus (AAV)-based gene therapy is a promising therapeutic approach; however, high production costs remain a significant barrier to broader clinical adoption. PackGene has developed innovative solutions to address these challenges by enhancing AAV manufacturing efficiency and reducing costs. Key advancements include a high-yield monoclonal AAV production cell line, optimized Rep-Cap (RC) plasmid designs, and a dual plasmid system that improves both productivity and vector quality. Additionally, the π-Icosa capsid engineering platform enhances AAV delivery efficiency. Together, these innovations enable scalable, cost-effective AAV production, reducing manufacturing expenses while ensuring high-quality vector output. These improvements pave the way toward more accessible gene therapies, benefiting patients globally and driving future clinical and commercial success.